SEC Form 4 · accession 0001209191-17-045514
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asaf Danziger
Officer — Chief Executive Officer · Director
Period of report
Jul 14, 2017
Accepted (ET)
Jul 18, 2017 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jul 14, 2017 | M | 354,780 | $0.38 | A | 812,362 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF1 | $0.38 | Jul 14, 2017 | M | 354,780 | D | — | Oct 12, 2020 | Ordinary Shares | 354,780 | 0 | D |
Explanation of responses
- F1Fully vested and currently exercisable as of the date hereof.